NMC
TEVA icon

Nine Masts Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Nine Masts Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-80,000
Closed -$174K – 253
2018
Q4 		$174K Buy
80,000
+79,200
+9,900% +$1.62M 0.03% 120
2018
Q3 		$43K Hold
800
– – 0.01% 260
2018
Q2 		$50K Sell
800
-809
-50% -$16.5K 0.01% 246
2018
Q1 		$504K Buy
+1,609
New +$31.4K 0.08% 98

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nine Masts Capital's TEVA Position: Q1 2019 in Review

Nine Masts Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 67,227 shares — an estimated $1.04M sold.

Nine Masts Capital first reported a position in TEVA in Q1 2018 and held it in 3 quarters. The position peaked at $1.04M in Q4 2018. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Nine Masts Capital reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Nine Masts Capital sold 67,227 Teva Pharmaceuticals shares in Q1 2019, an estimated $1.04M.
  • Nine Masts Capital first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Nine Masts Capital's Teva Pharmaceuticals position peaked at $1.04M in Q4 2018.
  • 521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Nine Masts Capital's 13F filing for Q1 2019, filed 6 May 2019.